Low Float (Nasdaq: ALZN) Reports Positive Topline Data From Key Phase II Clinical Trial

Alzamend Neuro, Inc. (Nasdaq: ALZN) just dropped some seriously game-changing news this morning.

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored Low Float (Nasdaq: ALZN) Reports Positive Topline Data From Key Phase II Clinical Trial *Click Here To Get Our Alerts Faster Via SMS* March 26th Greetings Readers, Alzamend Neuro, Inc. (Nasdaq: ALZN) just dropped some seriously game-changing news this morning. Flying under-the-radar so far, here's what's cooking: Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions Bioequivalence Confirmed: AL001 delivered 101% of total lithium blood exposure and 97% of peak lithium levels vs. standard lithium carbonate Superior Brain Penetration: AL001 showed numerically higher lithium concentrations in all measured brain regions, including whole brain Faster Brain Uptake: AL001 reached peak brain concentration in 6.7 hours vs. 8.4 hours for standard lithium carbonate ATLANTA, March 26, 2026 /PRNewswire/ -- Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), ..., today announced positive topline data from its first Phase II "Lithium in Brain" clinical trial in healthy human subjects, demonstrating that AL001 meets bioequivalence standards while also showing numerically superior lithium delivery to the brain compared to standard lithium carbonate across all 26 measured brain regions including whole brain. These results suggest a promising differentiated pharmacological profile with significant implications for patients with Alzheimer's, BD, MDD and PTSD. The trial was conducted at Massachusetts General Hospital ("MGH") and represents a meaningful clinical and regulatory advance for AL001. ... "These data mark a pivotal advancement in the development of AL001," said Stephan Jackman, CEO of Alzamend. "We have clinical evidence that AL001 shows equivalent delivery of lithium in the bloodstream compared to standard lithium carbonate capsules, which is a key regulatory safety measure. And the brain data, while preliminary, show a consistent increase providing higher lithium in every brain region we measured. This can permit lower systemic doses to achieve efficacy thereby providing an enhanced safety profile. Combined with the faster brain uptake, we believe AL001 has a meaningfully differentiated profile compared to conventional lithium; one that could benefit the 43+ million Americans afflicted with Alzheimer's, BD, MDD and PTSD." ... Read the full article here. Don't forget. ALZN is a low float idea. With fewer than 4Mn shares in its float, the potential for heightened volatility may be significant. Spend a moment now to review our complete (Nasdaq: ALZN) report below and consider this profile for your watchlist. ----- For more than fifty years, one of the most well-known compounds in medicine has proven its worth again and again. Few treatments can match its long track record of effectiveness. The catch? Its impact may have been limited by how it’s been delivered—until now. A new method is starting to make waves for tackling that core issue head-on, and it’s getting plenty of attention from researchers, doctors, and biotech watchers alike. All eyes are on key data expected in early 2026, as many are eager to see whether this next step can unlock more of the compound’s potential. That growing interest helps explain why Alzamend Neuro, Inc. (Nasdaq: ALZN) landed on our radar and is topping our watchlist this Thursday. A quick note on this profile: according to Yahoo Finance, ALZN has fewer than 4Mn shares available to the public. When companies have a small float, the potential for heightened volatility could be significant. We’ve already seen signs of that. Over the past month and a half, ALZN climbed about 46%, rising from roughly $1.61 on February 13th to $2.35+ on March 16th. And there’s more buzz building. Analyst Edward Woo, CFA, at Ascendiant Capital Markets, recently set a price target of $28 for ALZN. That’s more than a 1,300% potential upside compared to ALZN's opening valuation on Wednesday. ALZN is developing a re-engineered version of lithium designed to reach the brain more effectively while limiting toxic side effects elsewhere in the body. As the company approaches this important milestone, the biotech world is watching for results that could reshape the standard of care for a vast number of patients living with Alzheimer’s and psychiatric disorders. ALZN's Mission To Modernize Neuroscience Alzamend Neuro, Inc. (Nasdaq: ALZN) is a clinical-stage biopharmaceutical company dedicated to developing novel products that address the massive unmet needs in the treatment of Alzheimer’s disease, bipolar disorder, major depressive disorder (MDD), and post-traumatic stress disorder (PTSD). Unlike many biotechnology firms that chase entirely unproven biological targets, ALZN is utilizing a "known quantity" approach by taking lithium—a mineral with decades of proven efficacy—and optimizing its delivery through cutting-edge chemical engineering. The company’s strategy is built on the reality that while lithium is one of the most effective tools in a psychiatrist's arsenal, its "old-school" formulations are fraught with complications. Current lithium salts, like lithium carbonate, often struggle to cross the blood-brain barrier efficiently. This forces doctors to prescribe higher doses, which leads to high concentrations in the bloodstream. These systemic levels can be detrimental to the kidneys and thyroid, requiring patients to undergo lifelong, invasive blood monitoring. ALZN intends to break this cycle of toxicity with its primary candidate, AL001. ALZN Pipeline Overview Alzamend Neuro, Inc. (Nasdaq: ALZN)’s research program currently includes two primary therapeutic candidates focused on neurological and psychiatric conditions.  ALZN’s lead program, AL001, is a patented ionic cocrystal formulation of lithium designed to improve how lithium reaches the brain and is being studied for Alzheimer’s disease, bipolar disorder, major depressive disorder, and PTSD. In addition to AL001, ALZN is also developing ALZN002, a cell-based immunotherapy approach designed to stimulate the immune system to help combat Alzheimer’s disease by targeting beta-amyloid buildup in the brain. AL001: The Ionic Cocrystal Breakthrough At the heart of the Alzamend Neuro story is AL001, a patented ionic cocrystal of lithium, salicylate, and L-proline. This is not just a new pill; it is a sophisticated delivery vehicle designed to improve the pharmacokinetics of lithium. By combining these specific compounds, the AL001 formulation is designed to improve how lithium reaches the brain. In preclinical mouse studies, this technology demonstrated a remarkable ability to achieve higher brain uptake while maintaining lower levels in the blood compared to standard lithium carbonate. This "brain-first" approach is particularly vital for the company’s target indications. For an Alzheimer’s patient, the goal is neuroprotection and the reduction of cognitive decline; for a patient with bipolar disorder, it is mood stabilization. Both require the drug to reach the central nervous system. By potentially achieving therapeutic brain exposure with a lower systemic dose, ALZN aims to offer the benefits of lithium without the constant threat of organ damage. The "Lithium In Brain" Phase II Potential Catalyst The most anticipated milestone for Alzamend Neuro is the upcoming topline data from its Phase II "Lithium in Brain" study, conducted in partnership with Massachusetts General Hospital. This is not a standard clinical trial; it utilizes state-of-the-art 7Li MRI technology equipped with a custom-built head coil. This advanced imaging allows researchers to literally map lithium inside the human brain in real-time. The study compares AL001 head-to-head with a marketed lithium carbonate product in healthy subjects. The goal is to determine whether ALZN's formulation can deliver more lithium to specific brain structures while maintaining safer blood levels compared with lithium carbonate. The clinical portion of this trial was completed in late 2025, and the topline data is expected in the first quarter of 2026. This data meaningfully advances the demonstration of P-O-C for the AL001 platform. Removing Commercial Barriers: The TDM Factor One of the greatest barriers to lithium adoption is therapeutic drug monitoring (TDM). Because the line between a therapeutic dose and a toxic dose is so thin with traditional lithium, patients must have their blood drawn frequently. This is a massive inconvenience for patients and a significant liability for physicians. ALZN believes that because AL001 can maintain safer systemic levels, it may eliminate the need for TDM. If the FDA eventually approves a lithium treatment that does not require constant blood tests, the market potential could expand exponentially. It would allow lithium to be prescribed more freely in primary care settings and for fragile populations, such as the elderly, who often have compromised kidney function and cannot risk standard lithium therapy. Market Potential And Strategic Positioning The commercial landscape for AL001 is broad. Alzheimer’s disease alone remains one of the largest unmet-need markets in global medicine, where even therapies with modest cognitive benefits can generate significant annual sales. By targeting four major indications—Alzheimer’s, Bipolar, MDD, and PTSD—Alzamend Neuro is positioning AL001 as a platform-level asset. The company is led by an experienced management team and guided by a Scientific Advisory Board that includes world-renowned experts in neuroscience. This leadership has been instrumental in securing partnerships with top-tier institutions like Massachusetts General Hospital and ensuring that the clinical program is designed to meet the highest regulatory standards. Grab Sources And More Here: ALZN Website. ALZN Presentation. ----- 7 Key Potential Catalysts Pin (ALZN) To The Top Of Thursday's Watchlist #1. Low Float: With fewer than 4Mn shares available to the public according to Yahoo Finance, ALZN’s small float could have the potential to witness big moves if demand begins to shift. #2. Recent Momentum: Over the past month and a half, ALZN made an approximate 46% move, from around $1.61 on February 13th to $2.35+ on March 16th. #3. Analyst Target: Ascendiant Capital Market analyst Edward Woo, CFA, recently highlighted a $28 target on ALZN, which suggests over 1,300% upside potential from its open on Wednesday. #4. Upcoming Data: Topline results from the Phase II “Lithium in Brain” study involving ALZN are expected in early 2026, creating a widely watched scientific milestone for the company. #5. Advanced Imaging: Researchers evaluating ALZN are using specialized 7Li MRI mapping technology that can measure lithium distribution inside the human brain in real time. #6. Novel Formulation: The patented ionic cocrystal used by ALZN combines lithium, salicylate, and L-proline in a formulation designed to improve how lithium reaches the brain. #7. Large Indications: The development program surrounding ALZN is focused on Alzheimer’s disease, bipolar disorder, major depressive disorder, and PTSD—four major neurological and psychiatric conditions with substantial global patient populations. ----- We're officially kicking-off coverage on Alzamend Neuro, Inc. (Nasdaq: ALZN). Be on the watch for updates heading your way soon. Talk shortly. Sincerely, Kai Parker StockWireNews (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)

SWN Media | 160 W. Camino Real Unit 886 | Boca Raton, FL 33432 US Unsubscribe | Update Profile | Constant Contact Data Notice